Hints and tips:
...Nick Jackson, who oversees vaccine R&D at the Coalition for Epidemic Preparedness Innovations, part of Covax, said it now feels “enormously relieved and quite vindicated” that it invested almost $400m in...
...To be fair, many have escaped to the seaside towns outside of New York City since the widespread coronavirus lockdowns in March, but few are getting R&R at the moment....
...“We want to add to our pipeline organically through our own R&D and through acquisitions,” he said, adding that the proceeds would not go to paying down debt....
...J&J said its consumer health division benefited from increased demand driven by the coronavirus pandemic, with sales rising 11 per cent in the quarter to $3.6bn....
...AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal...
...Allergan has a strong long-term outlook across its four key therapeutics areas and a highly promising R&D pipeline.”...
...For instance, it paid $4.2bn of interest over the first six months of 2018 — more than the revenues of 259 of the S&P 500's constituents in the same period, according to S&P Capital IQ....
...A significant slowdown could, therefore, have a substantial impact on citizens’ financial health....
...H & R Block, meanwhile, was the biggest decliner on the benchmark index, tumbling nearly 19 per cent to $24.04 after issuing disappointing margin guidance....
...The swift unravelling of the toy seller, at $6.9bn the third-largest retail bankruptcy in history, jolted vendors, who are critical to a retailer’s health....
...In July, DWCP sold a portfolio worth more than $9.4bn to Guangzhou-based developer R&F as well as acquisitive property developer Sunac....
...But now the humble pakora — and its makers — have emerged at the heart of a passionate debate about India’s economic health....
...Health....
...And while R&D and marketing dollars have shifted up in recent years, Pepsi has wrung operating cost savings elsewhere, alongside tightening cash spend on working capital....
...R&D budgets at about $9bn a year....
...US earnings The US is nearly three quarters of its way through earnings season but more than 120 companies on the S&P 500 are slated to report results this week....
...Critics have accused GSK of turning away from R&D after its $20bn asset swap with Novartis deepened the company’s diversification into vaccines and consumer health....
...But Nike had good news, with shares rising 5 per cent to $120.68 in after hours trading on a strong profits beat. The S&P 500 fell 0.34 per cent to 1,932.24....
...This has left the company’s share price almost unchanged over the period while the S&P pharmaceuticals index has doubled....
...Downward pricing pressure hitherto associated with the cash-strapped public health systems of Europe has been spreading across the Atlantic, as the US gets serious about cutting waste from its private health...
...Whether the ex-JPMorgan executive’s performance will, in time, be hailed as a coup de theatre, depends largely on the health of Asian economies and the success with which Standard Chartered builds up its...
...But they are joined by well-known US companies such as Weight Watchers, Toys R Us, Sears, and Advanced Micro Devices, a chipmaker....
...Groups from Macy’s to Urban Outfitters have reported falling revenues and missed analysts’ estimates in recent days, pushing the S&P Retail Select Industry Index down 8.5 per cent last week to mark the sector...
...This optimism is reflected in the 40 per cent jump in the S&P pharmaceuticals index over the past year, compared with a 7 per cent rise in the broader S&P 500....
...Over the past five years CSL has invested US$2bn in R&D and employs more than 1,000 scientists....
International Edition